Clinical trials: Pancreatic Neuroendocrine Neoplasm
Neuroendocrine Tumors
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
The study will be conducted to compare the safety and efficacy of Capecitabine Combined With Dacarbazine(CAPDTIC) and Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal…
- Trial name
- NCT03279601
- Testing
- Capecitabine, Dacarbazine, Capecitabine, Temozolomide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Peking University
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Trial name
- NCT00416767
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Volunteers
- 20 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Islet Cell Tumor, Pancreatic Cancer
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic…
- Conditions
- Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease, Acute Pancreatitis
- Trial name
- NCT00830557
- Testing
- medical chart review, survey administration, biospecimen collection
- Where
- 3 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma
- Trial name
- NCT02498665
- Testing
- DSP-7888 Dosing Emulsion
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Endoscopic Ultrasound-Guided Radiofrequency Ablation, Pancreatic Neuroendocrine Tumors (pNET)
Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors
The primary aim of this study is to evaluate the technical feasibility and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in the treatment of pancreatic cystic neoplasms (PCNs) and pancreatic…
- Conditions
- Endoscopic Ultrasound-Guided Radiofrequency Ablation, Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Cystic Neoplasms
- Trial name
- NCT07536087
- Testing
- Endoscopic ultrasound-guided radiofrequency ablation for pancreatic cystic lesions, Endoscopic ultrasound-guided radiofrequency ablation of pancreatic solid lesions
- Where
- Czechia
- Volunteers
- 50 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Soft Tissue Sarcoma, Colorectal Cancer
A Safety Study of SGN-CD47M in Patients With Solid Tumors
This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma
- Trial name
- NCT03957096
- Testing
- SGN-CD47M
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Seagen Inc.
Neuroendocrine Tumor of Pancreas, Multiple Endocrine Neoplasia Type 1
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Patients with the Multiple Endocrine Neoplasia type 1 (MEN1) syndrome are genetically predisposed for developping multiple pancreatic neuro-endocrine tumours (pNET).
- Trial name
- PRIME (NCT05037461)
- Testing
- High-dose-high precision MR-guided radiotherapy
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- J.M. de Laat
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Advanced Solid Tumors Cancer
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when…
- Trial name
- NCT02988960
- Testing
- ABBV-927, ABBV-181
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 163 people
- Sponsor
- AbbVie
Pancreatic Cancer, Breast Cancer
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
Here's a polished version of the text: "This project involves patients with high-expression LRRC15 malignant tumors who are either clinically suspected of or diagnosed with pancreatic cancer, breast cancer, lung cancer, ovarian…
- Conditions
- Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma
- Trial name
- NCT07651020
- Testing
- Specific SPECT imaging agents targeting LRRC15
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Pancreatic Neuroendocrine Tumors
A Clinical Risk Score to Stratify High-risk PanNETs
Considerable heterogeneity exists in the risk of recurrence after curative resection of pancreatic neuroendocrine tumors (PanNETs).
- Trial name
- NCT07695532
- Testing
- Curative surgical resection
- Where
- China
- Volunteers
- 552 people
- Sponsor
- Fudan University
Pancreatic Cancer
Two Chemotherapy Regimens Plus or Minus Bevacizumab
Compare the effect of capecitabine (cape) + temozolomide (temo) and of 5FU + streptozotocin (strepto) given with a new schedule (LV5FU2 + strepto), two of the most used chemotherapy regimens in the treatment of well…
- Trial name
- BETTER2 (NCT03351296)
- Testing
- LV5FU2, Streptozocin, Capecitabine
- Where
- 20 sites in France
- Volunteers
- 140 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Neuroendocrine Carcinoma
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
The study will be conducted to compare the safety and efficacy of irinotecan combined with cisplatin (IP regimen) and etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal pancreatic and…
- Trial name
- NCT03168594
- Testing
- irinotecan cisplatin, Etoposide cisplatin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be…
- Conditions
- Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Refractory Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02893930
- Testing
- Sapanisertib
- Where
- 405 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma
A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
There are several types of early pre-cancerous lesions found in the pancreas which have the potential to develop into pancreatic cancer.
- Trial name
- PaC-MAn (NCT03840460)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreas Cancer, Melanoma
Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.
Individuals who are affected with pancreas cancer and melanoma as well as those without either cancer who have been identified as 1st or 2nd degree relatives of family members with pancreas cancer and melanoma will be asked to…
- Trial name
- TCOG (NCT03174574)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pancreatic Neuroendocrine Tumor
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, that tend to be slow growing and are often diagnosed when metastatic.
- Trial name
- NeoNet (NCT05568017)
- Testing
- peptide receptor radionuclide therapy with Y-90-DOTATOC
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- European Institute of Oncology
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Gastroenteropancreatic Neuroendocrine Tumors
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
The purpose of the study is to evaluate the efficacy and tolerability of the combination of Lanreotide Autogel 120 mg and Temozolomide in patients with progressive gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) graded…
- Trial name
- SONNET (NCT02231762)
- Testing
- Lanreotide Autogel 120 mg, Temozolomide (TMZ)
- Where
- 10 sites in Austria, Germany
- Volunteers
- 57 people
- Sponsor
- Ipsen